Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
May 12, 2026
Dr. Reddy's Laboratories (RDY): Q4 FY26 Earnings Preview Amid U.S. Headwinds and Pipeline Promise

Dr. Reddy's Laboratories (RDY): Q4 FY26 Earnings Preview Amid U.S. Headwinds and Pipeline Promise

Key Takeaways

  • Analysts expect Q4 FY26 revenue of approximately $887 million, a potential decline due to softer U.S. generics sales.
  • Consensus EPS (earnings per share) estimate stands at $0.09 per ADS (American Depositary Share).
  • U.S. business faces headwinds from lower lenalidomide (gRevlimid) sales and pricing pressures, offsetting growth in emerging markets and India.
  • Q3 FY26 saw revenue of $971 million, up 4.4% YoY (year-over-year), providing a resilient base amid challenges.
  • Investors watching for FY27 guidance, biosimilar pipeline updates, and margin outlook post-Q4.

Earnings Context and Why It Matters

I've been keeping a close eye on Dr. Reddy's Laboratories (RDY), a leading global pharmaceutical company, as it approaches its fiscal Q4 FY26 earnings release for the period ended March 31, 2026. This report wraps up a year marked by mixed results, where robust growth in India and emerging markets has helped counterbalance pressures in the U.S. generics segment from pricing erosion and fading lenalidomide contributions. From what I see, the outcomes here will shed light on how well the company is executing on complex generics and its branded portfolio as these mature and biosimilars like semaglutide and abatacept move forward. For investors like us, the spotlight falls on trends in North America—RDY's biggest market—and any pipeline updates, especially against broader industry challenges such as elevated freight costs and regulatory obstacles. The company's track record of beats, like in Q3 when revenue exceeded estimates, suggests room for positive surprises that could shape its valuation in this competitive pharma space.

Earnings Expectations

Wall Street is looking for consolidated Q4 FY26 revenue of around $886.6 million, which would mark a sequential drop from Q3's $971 million and a possible 3-4% year-over-year decline, largely tied to softer U.S. performance. In INR, that translates to roughly ₹8,220 crore, down from ₹8,506 crore a year ago, according to analyst previews that point to higher freight expenses and subdued gRevlimid sales. The EPS consensus sits at $0.09 per ADS, below the $0.16-$0.20 range of recent quarters, as margin pressures weigh in—EBITDA could fall about 20% year-over-year.

Looking back, the company has shown resilience: Q3 revenue topped estimates by about 0.6% with 4.4% YoY growth, though EPS came in line, and shares dipped premarket on profit worries. Metrics I'm watching include U.S. generics volumes, India formulations growth (which has been double-digit historically), gross margins around 53-54%, and R&D investment in biosimilars. Management has stressed the strength of its base business, and any FY27 guidance pointing to 5%+ full-year growth—aligning with the FY26 consensus of ₹343 billion—could shift sentiment meaningfully.

Market Reaction and Investor Sentiment

As we head into the Q4 earnings on May 12, 2026—before the market opens, with the call at 10:00 AM ET—sentiment around RDY feels cautious. Shares have moved sideways lately, mirroring concerns from previews about U.S. declines, like the roughly 12% YoY drop in Q3 North America sales. Reactions to past reports have been mixed: Q3's beat brought an initial dip followed by recovery, and prior beats saw upside in 6 out of 10 cases, though with an average first-day move potential of -8.2%. Downside risks stem from more gRevlimid erosion and forex fluctuations (INR/USD), but emerging markets growth—at 32% in Q3—could provide an upside surprise. Implied volatility points to a 5-7% post-earnings move.

Forward Outlook and Key Factors to Monitor

After Q4, the focus will turn to FY27 guidance, with a pipeline loaded with biosimilars and complex generics. Management has consistently aimed for double-digit base growth excluding lenalidomide, and FY26 consensus suggests about a 5.5% revenue increase to ₹343 billion. One thing that stands out is the need to track U.S. generics stabilization, where pricing pressures may ease even as competition heats up.

Pipeline catalysts are a big part of the story: approvals for semaglutide (a GLP-1 akin to Ozempic) in Canada and elsewhere by late FY26 or FY27, along with abatacept (Orencia biosimilar) and ustekinumab, could add more than 10% to incremental revenue. India, with its strong double-digit Q3 growth, and emerging markets up 32% YoY remain solid performers, further supported by the nicotine OTC acquisition.

Margins will get close scrutiny too: Q3 adjusted EBITDA was 24.8%, so I'll be looking at cost controls, freight normalization, and R&D spending (around 8-10% of sales) amid labor code effects. Other dynamics include U.S. FDA inspections, India formulations pricing, and forex tailwinds. Strong execution across these could reinforce the mid-teens growth path.

Leveraging Tickeron’s AI Screener in My Analysis

In digging into RDY ahead of earnings, I also checked this using Tickeron’s AI Screener, which helps me filter stocks and ETFs based on technical patterns, fundamentals, trends, volatility, and AI signals. It scans thousands of names with customizable filters like industry peers, market cap, indicators, price patterns, and performance metrics—making it easier to spot trade ideas, breakouts, or opportunities in pharma and beyond. I find it streamlines my data-driven process, especially for comparing RDY to sector peers during volatile periods like earnings season.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations

Related Ticker: RDY

RDY in upward trend: price expected to rise as it breaks its lower Bollinger Band on June 02, 2026

RDY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 51 cases where RDY's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where RDY's RSI Indicator exited the oversold zone, of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The 10-day moving average for RDY crossed bullishly above the 50-day moving average on May 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RDY advanced for three days, in of 323 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on June 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RDY as a result. In of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for RDY turned negative on June 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .

RDY moved below its 50-day moving average on June 01, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RDY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.801) is normal, around the industry mean (145.700). P/E Ratio (24.665) is within average values for comparable stocks, (95.785). RDY's Projected Growth (PEG Ratio) (3.683) is slightly higher than the industry average of (1.730). Dividend Yield (0.007) settles around the average of (0.033) among similar stocks. P/S Ratio (3.146) is also within normal values, averaging (117.044).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. RDY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RDY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Bausch Health Companies (NYSE:BHC), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 3.96B. The market cap for tickers in the group ranges from 2.12K to 63.66B. AGN holds the highest valuation in this group at 63.66B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -5%. For the same Industry, the average monthly price growth was 16%, and the average quarterly price growth was 11%. CABR experienced the highest price growth at 14%, while PRFX experienced the biggest fall at -47%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -36%. For the same stocks of the Industry, the average monthly volume growth was -22% and the average quarterly volume growth was -5%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 67
Price Growth Rating: 59
SMR Rating: 87
Profit Risk Rating: 84
Seasonality Score: 17 (-100 ... +100)
View a ticker or compare two or three
RDY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a developer of pharmaceuticals

Industry PharmaceuticalsGeneric

Profile
Details
Industry
Pharmaceuticals Generic
Address
8-2-337, Road No. 3
Phone
+91 4049002900
Employees
25863
Web
https://www.drreddys.com
Interact to see
Advertisement
Oracle Corporation (ORCL) has shown resilience in a volatile tech sector, maintaining a market capitalization around $590 billion amid broader market fluctuations. The stock trades within its 52-week range, reflecting investor responses to cloud computing demand and competitive pressures. Recent trading sessions have seen downward momentum, influenced by sector-wide reevaluations of AI investments and macroeconomic uncertainties. Despite this, ORCL's forward price-to-earnings ratio and dividend yield position it as a stable player in enterprise software, with focus on its multicloud strategy and partnerships driving long-term value in the latest market cycle.
NuScale Power (SMR) has experienced notable volatility in recent trading sessions, reflecting broader trends in the nuclear energy sector. The stock has traded within a wide range over the latest market cycle, influenced by shifts in investor sentiment toward small modular reactors amid rising energy needs from data centers and AI applications. While the company maintains a market capitalization in the mid-single-digit billions, its price action has been marked by pullbacks from earlier peaks, with momentum indicators suggesting potential stabilization. Broader industry factors, including regulatory support and partnerships, continue to underpin interest, though operational challenges persist. This positions SMR as a high-beta play in the clean energy space, appealing to growth-oriented investors monitoring sector developments.
Monolithic Power Systems (MPWR) has demonstrated robust performance in recent trading sessions, buoyed by its position in the semiconductor industry amid rising demand for power management solutions in AI and data centers. The stock has maintained upward momentum over the latest market cycle, reflecting broader sector trends where technology firms benefit from enterprise investments. With a market capitalization in the mid-$40 billion range and a forward price-to-earnings ratio indicating growth expectations, MPWR continues to attract investor interest. Recent weeks have seen the shares navigate volatility tied to macroeconomic factors, yet overall sentiment remains positive as the company leverages its fabless model to capitalize on efficiency-driven innovations in computing and automotive applications.
Quanta Services (PWR), a leader in infrastructure solutions for electric power, renewables, and communications, has demonstrated resilient performance in recent trading sessions. The stock has maintained upward momentum amid broader market cycles favoring energy and infrastructure sectors, driven by increasing demand for grid modernization and sustainable projects. Trading near its 52-week highs, PWR reflects positive investor sentiment, with a market capitalization exceeding $68 billion and a trailing P/E ratio around 68. Volatility has been moderate, influenced by sector-wide catalysts, positioning the company as a growth-oriented pick in the industrial space. This stock analysis highlights PWR's ability to capitalize on long-term trends in energy transition.
Teradyne (TER), a leader in automated test equipment and industrial robotics, has demonstrated resilient performance amid a favorable semiconductor market cycle. In recent weeks, the stock has maintained upward traction, outperforming broader indices like the Nasdaq, supported by AI-driven demand for chip testing solutions.
Curtiss-Wright Corporation (CW) has demonstrated resilience in recent trading sessions, navigating a period of moderate volatility within the aerospace and defense sector. The stock has shown upward momentum over the latest market cycle, supported by strong demand in commercial and military applications.
CrowdStrike Holdings (CRWD) has shown resilience in the cybersecurity sector amid broader market cycles, with shares experiencing moderate pullbacks in recent weeks following strong year-to-date gains. The stock trades near its upper range, reflecting investor optimism in AI-driven security innovations and platform adoption.
Arista Networks (ANET) has demonstrated resilience in recent trading sessions amid fluctuating tech market conditions. The stock has navigated broader sector headwinds, including competition in cloud networking and varying demand from hyperscale clients.
Galaxy Digital Holdings Ltd. (GLXY), a leading player in digital assets and blockchain investment, has shown resilience in recent trading sessions amid cryptocurrency market dynamics. The stock has navigated volatility driven by Bitcoin's price fluctuations, reflecting broader sector sentiment.
In the ever-shifting healthcare sector, CVS Health (CVS) and UnitedHealth Group (UNH) represent two powerhouse approaches: CVS as a retail pharmacy giant with integrated insurance and services, and UNH as a leading health insurer with diversified operations.
In the competitive retail landscape, American Eagle Outfitters (NYSE: AEO) is showing signs of robust upward potential as it navigates a strong 2025 performance.
In the dynamic world of satellite communications and broadband services, EchoStar Corporation (NASDAQ: SATS) has captured investor attention with a notable technical breakthrough. On December 8, 2025, the stock's 10-day moving average crossed above its 50-day moving average, signaling the onset of a bullish upward trend.
In an era where global investors demand instant access to markets, major players in the financial world are racing to extend trading hours beyond the traditional 9:30 a.m. to 4 p.m. ET window. This push is driven by surging foreign holdings of U.S. equities, which hit $17 trillion last year, and the growing appetite for nonstop trading in a 24/7 digital economy.
In the resilient gold mining sector, IAMGOLD Corporation (NYSE: IAG) has demonstrated an extraordinary uptrend throughout 2025, capitalizing on rising gold prices and operational milestones.
Within the rapidly evolving automotive retail landscape, Carvana Co. (NYSE: CVNA) has emerged as one of 2025’s standout performers. Once viewed as a highly volatile name, the company has transformed into a market leader as demand for online vehicle purchasing accelerates
Microsoft (MSFT) emerges as the AI-favored stock in 2025, outperforming Apple (AAPL) with a 16% year-to-date gain, compared to Apple’s 10% rise. The advantage stems from Microsoft’s deeper enterprise AI integration, accelerating cloud growth, and scalable software ecosystem.
ExxonMobil (XOM) emerges as the AI-preferred energy stock in 2025, posting a 10% year-to-date gain compared with Chevron’s (CVX) 2% increase. Stronger upstream production, exposure to high-growth assets, and expanding low-carbon initiatives support XOM’s momentum. Tickeron’s AI models signal continued upside for XOM, while CVX shows signs of overbought conditions and elevated downside risk.
Tesla (TSLA) emerges as the AI-preferred EV stock in 2025, posting a 19% year-to-date gain, while BYD (BYDDY) has declined 82%, reflecting diverging momentum across the global EV market. Tickeron’s AI trading bots indicate strong bullish conditions for TSLA, supported by positive momentum signals, whereas BYDDY shows sustained bearish trends.
Broadcom (AVGO) emerges as the AI-preferred semiconductor stock in 2025, posting a 48% year-to-date gain, compared with 37% for NVIDIA (NVDA), supported by stronger diversification across networking, infrastructure, and custom AI chips.